Treadwell Therapeutics
New York
About Treadwell Therapeutics
Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer. Founded by a cadre of pre-eminent scientific luminaries, including Dr. Tak W. Mak, the Company's robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945, and a best-in-class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1. Treadwell also has a robust pre-clinical pipeline with multiple biologic and next-generation TCR-based autologous cell therapy programs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $118.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2021)
- Website: treadwelltx.com
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/treadwell-therapeutics-96489 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.